AI Article Synopsis
- The study investigates higher-grade transformation (HGT) from marginal zone lymphoma (MZL) to aggressive lymphoma, focusing on a cohort of 453 patients to analyze risk factors and the effect on overall survival (OS).
- Among the patients, 7.5% experienced HGT to diffuse large B-cell lymphoma, with significant predictors including elevated lactate dehydrogenase levels, involvement of multiple nodal sites, and not achieving complete remission after initial treatment.
- Patients with HGT had notably shorter overall survival rates, especially those who experienced HGT within 12 months of their MZL diagnosis, emphasizing the importance of early detection and treatment effectiveness.
Article Abstract
Purpose: Given the paucity of data on higher-grade transformation (HGT) to aggressive lymphoma in patients with marginal zone lymphoma (MZL), we report on a large cohort of patients, identify risk factors, and determine HGT impact on overall survival (OS).
Methods: We analyzed 453 patients with biopsy-proven MZL seen at our institution between 1995 and 2016. Kaplan-Meier, Cox proportional hazards regression, and competing risk methods were used in analyses of time-to-event outcomes.
Results: Thirty-four patients (7.5%) had biopsy-proven HGT to diffuse large B-cell lymphoma, including seven (21%) diagnosed at the time of initial MZL diagnosis. Among 27 incident patients, median time to HGT was 29 months (range, 1.3 to 135 months). Higher risk of HGT was observed in those with nodal/splenic MZL (subdistribution hazard ratio [SHR], 2.60; P = .023). On multivariable competing risk analysis, elevated lactate dehydrogenase (SHR, 2.71), more than four nodal sites (SHR, 2.97), and failure to achieve complete remission (CR) after initial treatment (SHR, 3.76) conveyed significantly higher risk for HGT ( P < .02). International Prognostic Index (IPI), Follicular Lymphoma IPI, and Mucosa-Associated Lymphoid Tissue Lymphoma IPI were only significant predictors of HGT univariably. Patients with HGT had shorter OS (5-year rate, 65% v 86%; P < .001). Patients who presented with HGT within 12 months since MZL diagnosis had shorter OS than those with HGT at MZL diagnosis combined with those with HGT more than 12 months later (4-year rate, 43% v 81%, P < .001). Non-CR and higher scores of IPI, Follicular Lymphoma IPI, and Mucosa-Associated Lymphoid Tissue Lymphoma IPI were the main significant predictors for shorter progression-free survival and OS.
Conclusion: Failure to achieve CR after initial treatment, elevated lactate dehydrogenase, and more than four nodal sites at the time of MZL diagnosis are the main predictors of increased risk of HGT. Patients with HGT have shorter OS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.18.00138 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A unique case of extranodal marginal zone lymphoma with synchronous pulmonary and dermatologic manifestations.
Respir Med Case Rep
December 2024
Division of Pulmonary and Critical Care, University of Rochester, Rochester, NY, USA.
An 89-year-old male with a medical history of non-ischemic cardiomyopathy was initially admitted with acute hypoxic respiratory failure attributed to heart failure exacerbation. Aside from progressive dyspnea, a non-pruritic, non-painful rash and constitutional symptoms were reported. Initial work-up was remarkable for normocytic anemia, lymphopenia, mild hypercalcemia, and elevated inflammatory markers.
View Article and Find Full Text PDFIntegration of CD200, CD43 and ROR1 in Multiparameter Flow Cytometry (MFC) Routine Panels for the Differential Diagnosis of B-cell lymphoproliferative Disorders (B-LPDs).
Mediterr J Hematol Infect Dis
January 2025
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy.
Background: Clonal mature B-cell lymphoproliferative disorders (B-LPDs) are a heterogeneous group of neoplasia characterized by the proliferation of mature B lymphocytes in the peripheral blood, bone marrow and/or lymphoid tissues. B-LPDs classification into different subtypes and their diagnosis is based on a multiparametric approach. However, accurate diagnosis may be challenging, especially in cases of ambiguous interpretation.
View Article and Find Full Text PDFLambda Light Chain Cast Nephropathy Caused by Splenic Marginal Zone Lymphoma.
Cureus
December 2024
Internal Medicine/Nephrology, Riverside Health System, Yonkers, USA.
We report an interesting case of an elderly male patient with splenic marginal zone lymphoma with a monoclonal cluster of differentiation (CD)5+ B cells. The patient developed signs of renal injury and was evaluated via serum protein electrophoresis and immunofixation electrophoresis, which revealed monoclonal gammopathy with elevated free lambda light chain. However, a bone biopsy ruled out a diagnosis of multiple myeloma.
View Article and Find Full Text PDFCD23 expression in lymphoplasmacytic lymphoma: Clinical-pathological and biological correlations.
Histopathology
December 2024
Pathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy.
Aims: The diagnosis of lymphoplasmacytic lymphoma (LPL) in the bone marrow (BM) is challenged by aberrant phenotypes and by overlapping histological features with marginal zone lymphoma (MZL). To address these issues, we (i) assessed LPL immunophenotype on a large series of BM samples, (ii) drew possible correlations between LPL phenotype and clinical/molecular data and (iii) investigated the role of new phenotypical markers in the differential diagnosis between LPL and MZL.
Materials And Methods: The study retrospectively considered 81 clinically annotated LPL diagnosed at Padua University Hospital (Padua, Italy) during a 5-year period.
Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia, a decade after the discovery of MYD88.
Hum Pathol
December 2024
Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address:
There has been remarkable progress over the past 80 years since Jan Waldenstrom first described patients with a hyperviscosity syndrome related to IgM paraprotein in 1944. The definition of Waldenstrom macroglobulinemia (WM) has evolved from a clinical syndrome to a distinct clinicopathologic entity with characteristic morphology, immunophenotype and molecular features. The landmark discovery of MYD88 mutation among most WM cases in 2012 marked the dawning of an era of molecular genomic exploration that led to a paradigm shift in clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!